Form 4: NeuroPace Inc. Chief Medical Officer Sells Shares Under 10b5-1 Trading Plan

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, sold 3,200 shares of common stock at an average price of $15.01 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Martha Morrell, the Chief Medical Officer of NeuroPace Inc., sold 3,200 shares of the company's common stock on January 24, 2025.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan.
• The shares were sold at a weighted average price of $15.01, with individual transactions ranging from $15.00 to $15.04 per share.
• Following the transaction, Ms. Morrell directly owns 87,062 shares of NeuroPace Inc. common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to sell shares under pre-arranged 10b5-1 trading plans to avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The use of a 10b5-1 trading plan is a common method for corporate insiders to sell shares while avoiding accusations of insider trading, and is a standard practice across the industry.
• The volume of shares sold is relatively small compared to the total outstanding shares of the company, and is not unusual for an executive sale.

Stakeholder Impact

• The sale of shares by a company officer may have a minor impact on shareholder sentiment, but the pre-arranged nature of the sale mitigates any significant concerns.

Key Dates

Keywords

NeuroPace Inc, insider trading, Form 4, Rule 10b5-1, stock sale, Martha Morrell, Chief Medical Officer